NO328361B1 - Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation - Google Patents

Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation Download PDF

Info

Publication number
NO328361B1
NO328361B1 NO20005637A NO20005637A NO328361B1 NO 328361 B1 NO328361 B1 NO 328361B1 NO 20005637 A NO20005637 A NO 20005637A NO 20005637 A NO20005637 A NO 20005637A NO 328361 B1 NO328361 B1 NO 328361B1
Authority
NO
Norway
Prior art keywords
hybrid protein
basophils
fragment
protease
protein
Prior art date
Application number
NO20005637A
Other languages
Norwegian (no)
Other versions
NO20005637D0 (en
NO20005637L (en
Inventor
Hans Bigalke
Juergen Frevert
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of NO20005637D0 publication Critical patent/NO20005637D0/en
Publication of NO20005637L publication Critical patent/NO20005637L/en
Publication of NO328361B1 publication Critical patent/NO328361B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a hybrid protein comprising or comprised of (i) a known protein which binds to mastocytes and/or basophils in a known manner and/or is absorbed thereby, and of (ii) a protease which splits one or more proteins of the secretory apparatus of the mastocytes and/or basophils.

Claims (7)

1. Hybridprotein, karakterisert ved at hybridproteinet omfatter: (i) et protein som binder til mastceller og/eller basofiler og/eller blir tatt opp av disse celler; og (ii) en protease som spalter ett eller flere av proteinene i sekresjonsapparatet til mastcellene og/eller basofilene.1. Hybrid protein, characterized in that the hybrid protein comprises: (i) a protein that binds to mast cells and/or basophils and/or is taken up by these cells; and (ii) a protease that cleaves one or more of the proteins in the secretion apparatus of the mast cells and/or basophils. 2. Hybridprotein, karakterisert ved at hybridproteinet omfatter: (i) et protein som binder til mastceller og/eller basofiler og/eller blir tatt opp av disse celler, hvorved proteinet (i) er valgt fra gruppen bestående av: IgE; IgE-fragment, spesielt IgE-Fc-fragment; antistoff mot IgE-reseptor på mastceller og/eller basofiler; fragment av antistoffet mot IgE-reseptor på mastceller og/eller basofiler, spesielt Fab-fragment; antistoff mot mastcellespesifikk kaliumkanal; og inaktivt men bindende MCD-peptid; og (ii) en protease som spalter ett eller flere av proteinene i sekresjonsapparatet til mastcellene og/eller basofilene.2. Hybrid protein, characterized in that the hybrid protein comprises: (i) a protein that binds to mast cells and/or basophils and/or is taken up by these cells, whereby the protein (i) is selected from the group consisting of: IgE; IgE fragment, especially IgE-Fc fragment; antibody against IgE receptor on mast cells and/or basophils; fragment of the antibody against the IgE receptor on mast cells and/or basophils, especially Fab fragment; antibody to mast cell-specific potassium channel; and inactive but binding MCD peptide; and (ii) a protease that cleaves one or more of the proteins in the secretion apparatus of the mast cells and/or basophils. 3. Hybridprotein, karakterisert ved at hybridproteinet omfatter: (i) et protein som binder til mastceller og/eller basofiler og/eller blir tatt opp av disse; og (ii) en protease som spalter ett eller flere av proteinene i sekresjonsapparatet til mastcellene og/eller basofilene, hvorved proteasen (ii) er valgt fra gruppen bestående av: lett kjede av et clostridium botulinumtoksin toksin, spesielt toksiner av typen A, B, Cl, D, E, F eller G; katalytisk aktivt fragment av den lette kjeden av et clostridium botulinum toksin, spesielt toksiner av typen A, B, Cl, D, E, F eller G; lett kjede av tetanus toksin (TeNT); katalytisk aktivt fragment av den lette kjeden av tetanus toksin; IgA-protease fra Neisseria gonorrhoeae; og katalytisk domene av IgA-proteasen fra Neisseria gonorrhoeae.3. Hybrid protein, characterized in that the hybrid protein comprises: (i) a protein that binds to mast cells and/or basophils and/or is taken up by them; and (ii) a protease that cleaves one or more of the proteins in the secretion apparatus of the mast cells and/or basophils, whereby the protease (ii) is selected from the group consisting of: light chain of a clostridium botulinum toxin toxin, especially toxins of type A, B, Cl, D, E, F or G; catalytically active fragment of the light chain of a clostridium botulinum toxin, especially toxins of type A, B, Cl, D, E, F or G; light chain of tetanus toxin (TeNT); catalytically active fragment of the light chain of tetanus toxin; IgA protease from Neisseria gonorrhoeae; and catalytic domain of the IgA protease from Neisseria gonorrhoeae. 4. Hybridprotein ifølge krav 2 eller 3, karakterisert v e d at proteinet (i) velges fra gruppen ifølge krav 2 og proteasen (ii) velges fra gruppen ifølge krav 3.4. Hybrid protein according to claim 2 or 3, characterized in that the protein (i) is selected from the group according to claim 2 and the protease (ii) is selected from the group according to claim 3. 5. Hybridprotein ifølge krav 4, karakterisert ved at i tillegg til den lette kjeden av et clostridium botulinum toksin eller av tetanustoksin, kan også den N-terminale delen av den tunge kjeden av det gjeldende toksinet (Hn-fragmentet), eller et fragment derav, være en del av hybridproteinet.5. Hybrid protein according to claim 4, characterized in that in addition to the light chain of a clostridium botulinum toxin or of tetanus toxin, the N-terminal part of the heavy chain of the relevant toxin (the Hn fragment), or a fragment thereof, can also be part of the hybrid protein. 6. Hybridprotein ifølge hvilket som helst av kravene 1 til 5, for inhibering av mastcelle-degranulasjon.6. Hybrid protein according to any one of claims 1 to 5, for inhibiting mast cell degranulation. 7. Anvendelse av et hybridprotein ifølge hvilket som helst av kravene 1 til 5, for fremstilling av et medikament for inhibering av mastcelle-degranulasjon.7. Use of a hybrid protein according to any one of claims 1 to 5, for the preparation of a medicament for inhibiting mast cell degranulation.
NO20005637A 1998-05-13 2000-11-08 Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation NO328361B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (en) 1998-05-13 1999-05-12 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Publications (3)

Publication Number Publication Date
NO20005637D0 NO20005637D0 (en) 2000-11-08
NO20005637L NO20005637L (en) 2000-11-08
NO328361B1 true NO328361B1 (en) 2010-02-01

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005637A NO328361B1 (en) 1998-05-13 2000-11-08 Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation

Country Status (22)

Country Link
EP (1) EP1084146B1 (en)
JP (1) JP4549533B2 (en)
KR (1) KR100580541B1 (en)
CN (1) CN1241945C (en)
AT (1) ATE227739T1 (en)
AU (1) AU755513B2 (en)
BR (1) BR9910359A (en)
CA (1) CA2331274C (en)
CU (1) CU22997A3 (en)
CZ (1) CZ294376B6 (en)
DE (1) DE59903410D1 (en)
DK (1) DK1084146T3 (en)
ES (1) ES2187200T3 (en)
HK (1) HK1036994A1 (en)
HU (1) HUP0103601A3 (en)
IL (2) IL139478A0 (en)
MX (1) MXPA00011148A (en)
NO (1) NO328361B1 (en)
PL (1) PL201879B1 (en)
PT (1) PT1084146E (en)
RU (1) RU2214420C2 (en)
WO (1) WO1999058571A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (en) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 Peptide for activating mast cell and immunomodulator comprising the same
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
BRPI0915142A8 (en) 2008-06-12 2018-01-02 Syntaxin Ltd POLYPEPTIDES, NUCLEIC ACID AND USES THEREOF
US8735133B2 (en) * 2008-07-31 2014-05-27 Total Marketing Services Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (en) * 2010-05-27 2014-05-14 四川大学 Recombinant IgE-Fc-anti EGFR single chain variable fragment fusion protein, its preparation method and its application
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL3242884T3 (en) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023018473A2 (en) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN AND INFLAMMATORY DISORDERS
KR20230163470A (en) 2021-03-30 2023-11-30 입센 바이오팜 리미티드 Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (en) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Use of 2-methoxyestradiol in the treatment of mastocytosis
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
RU2214420C2 (en) 2003-10-20
CN1300295A (en) 2001-06-20
JP2002514659A (en) 2002-05-21
KR20010042825A (en) 2001-05-25
ES2187200T3 (en) 2003-05-16
IL139478A0 (en) 2001-11-25
HUP0103601A2 (en) 2002-01-28
DE59903410D1 (en) 2002-12-19
EP1084146A2 (en) 2001-03-21
CZ294376B6 (en) 2004-12-15
EP1084146B1 (en) 2002-11-13
HUP0103601A3 (en) 2004-06-28
NO20005637D0 (en) 2000-11-08
JP4549533B2 (en) 2010-09-22
CA2331274C (en) 2010-04-06
AU755513B2 (en) 2002-12-12
BR9910359A (en) 2001-01-09
NO20005637L (en) 2000-11-08
PL344752A1 (en) 2001-11-19
WO1999058571A2 (en) 1999-11-18
CU22997A3 (en) 2004-10-12
CA2331274A1 (en) 1999-11-18
IL139478A (en) 2008-06-05
DK1084146T3 (en) 2003-02-03
CN1241945C (en) 2006-02-15
WO1999058571A3 (en) 2000-02-03
AU4260599A (en) 1999-11-29
CZ20004161A3 (en) 2001-04-11
HK1036994A1 (en) 2002-01-25
PL201879B1 (en) 2009-05-29
PT1084146E (en) 2003-02-28
ATE227739T1 (en) 2002-11-15
KR100580541B1 (en) 2006-05-16
MXPA00011148A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
NO328361B1 (en) Hybrid protein and its use for the preparation of a medicament for inhibiting mast cell degranulation
RU2000131217A (en) HYBRID PROTEIN FOR INHIBITING MASTOCYTE DEGRANULATION AND ITS APPLICATION
Schiavo et al. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus.
Patra et al. Quantitative proteomic analysis of venom from Southern India common krait (Bungarus caeruleus) and identification of poorly immunogenic toxins by immune-profiling against commercial antivenom
Kalb et al. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics
DE60131468D1 (en) HIGH-THROUGHPUT ASSAYS FOR PROTEOLYTIC ACTIVITIES OF CLOSTRIDIUM NEUROTOXINES
RU2545783C9 (en) Agents and methods for measuring polypeptide neurotoxin and its catalytic and proteolytic activities
Kalb et al. Three enzymatically active neurotoxins of Clostridium botulinum strain Af84: BoNT/A2,/F4, and/F5
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
Kalb et al. The use of Endopep-MS to detect multiple subtypes of botulinum neurotoxins A, B, E, and F
Rosen et al. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase–mass spectrometry assay
Hines et al. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E
Terilli et al. A historical and proteomic analysis of botulinum neurotoxin type/G
Volland et al. A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A
HUP0101987A2 (en) The induction of antibiotic peptides by lait (scd14) protein
DE69427484D1 (en) ANGIOTENSIN II RECEPTOR TYPE I SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMA
WO2005016232A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2010039748A3 (en) Botulinum neurotoxin e receptors and uses thereof
WO2005047305A3 (en) Cellular membrane protein assay
EP1629009B8 (en) Compositions comprising large and small binding fragments of antibodies against the same toxin
Noskova et al. Topology of the functions in molecule of staphylococcal enterotoxin Type A.
Keil Enzymic cleavage of proteins
EP2491384B1 (en) System for determining unprocessed and partially processed neurotoxin type a
Komarova et al. Conjugated fluorescent polymer sensor for proteolytic activity detection with designed specificity
DE69502095D1 (en) SOLID PHASE IMMUNOASSAY FOR DETECTING INHIBITORS FROM A PROTEOLYTIC ENZYME

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees